The latest update is out from Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ).
On March 12, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into an Underwriting Agreement with WestPark Capital, Inc. for a public offering of common stock and pre-funded warrants, which closed the following day. The company raised approximately $5.2 million in net proceeds, intended to fund its Phase II clinical trial for its lead product candidate, Ropidoxuridine, and for marketing, working capital, and general corporate purposes. This offering also helped Shuttle Pharma comply with Nasdaq’s minimum stockholders’ equity requirement, potentially averting delisting.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy. The company aims to develop therapies that enhance the effectiveness of radiation therapy while minimizing its side effects, thereby improving cancer cure rates, prolonging patient survival, and enhancing quality of life.
YTD Price Performance: -48.82%
Average Trading Volume: 122,327
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.07M
For detailed information about SHPH stock, go to TipRanks’ Stock Analysis page.